Lead Exposure and Prevention Advisory Committee, 55616 [2021-21807]
Download as PDF
<![CDATA[
55616
Federal Register / Vol. 86, No. 191 / Wednesday, October 6, 2021 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Lead Exposure and Prevention
Advisory Committee
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
CDC announces the following meeting
for the Lead Exposure and Prevention
Advisory Committee (LEPAC). This
meeting is open to the public by
teleconference but advance registration
by November 19, 2021 is needed to
receive the information to join the
meeting. The registration link is https://
www.zoomgov.com/webinar/register/
WN_qeMSB7npRJ23PTV6t1KMtQ.
DATES: The meeting will be held on
December 3, 2021, from 9:00 a.m. to
4:15 p.m., EST.
ADDRESSES: Register in advance at
https://www.zoomgov.com/webinar/
register/WN_qeMSB7npRJ23
PTV6t1KMtQ to receive the information
to join the meeting.
FOR FURTHER INFORMATION CONTACT:
Alexis Pullia, M.P.H., C.P.H., Committee
Management Specialist, National Center
for Environmental Health, CDC, 4770
Buford Highway, Atlanta, GA, 30341,
Telephone: (770) 488–3300; Email:
lepac@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The Lead Exposure and
Prevention Advisory Committee was
established under Section 2203 of
Public Law 114–322, the Water
Infrastructure Improvements for the
Nation Act; 42 U.S.C. 300j–27, Registry
for Lead Exposure and Advisory
Committee. The Secretary, Department
of Health and Human Services (HHS)
and by delegation, the Director, CDC
and Administrator, NCEH/ATSDR, are
authorized under Section 2203 of Public
Law 114–322 (42 U.S.C. 300j–27) to
review research and Federal programs
and services related to lead poisoning
and to identify effective services and
best practices for addressing and
preventing lead exposure in
communities.
The LEPAC is charged with providing
advice and guidance to the Secretary,
HHS, and the Director, CDC and
Administrator, ATSDR, on (1) reviewing
Federal programs and services available
to individual communities exposed to
lead; (2) reviewing current research on
lead exposure to identify additional
jspears on DSK121TN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
20:38 Oct 05, 2021
Jkt 256001
research needs; (3) reviewing and
identifying best practices, or the need
for best practices regarding lead
screening and the prevention of lead
poisoning; (4) identifying effective
services, including services relating to
healthcare, education, and nutrition for
individuals and communities affected
by lead exposure and lead poisoning,
including in consultation with, as
appropriate, the lead exposure registry
as established in Section 2203 (b) of
Public Law 114–322; and (5)
undertaking any other review or
activities that the Secretary determines
to be appropriate.
Matters To Be Considered: The agenda
will include updates on the blood lead
reference value, lead-related activities
from Federal LEPAC Members, the 1988
CLIA Amendment, and from Federal
environmental justice efforts focused on
lead, a discussion of best practices for
increasing and enhancing screening in
underserved populations, and
presentations on mapping efforts to
identify populations at higher risk of
lead exposure and Lead Safe Cleveland.
Agenda items are subject to change as
priorities dictate.
Public Participation
Procedure for Oral Public Comment:
The public comment period is
scheduled on December 3, 2021 from
11:05 a.m. until 11:20 a.m. Individuals
wishing to make a comment during the
public comment period, please email
your name, organization, and telephone
number by November 19, 2021, to
LEPAC@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–21807 Filed 10–5–21; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2020–D–1396]
Use of Data From Foreign
Investigational Studies To Support
Effectiveness of New Animal Drugs;
Guidance for Industry; Availability
Food and Drug Administration,
Health and Human Services (HHS).
ACTION: Notice of availability.
AGENCY:
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of a final
guidance for industry #265 entitled
‘‘Use of Data from Foreign
Investigational Studies to Support
Effectiveness of New Animal Drugs.’’
The guidance describes FDA’s current
thinking with respect to assisting
sponsors in incorporating data from
foreign countries into proposed clinical
investigational protocols and
applications for new animal drugs
under the Federal Food, Drug, and
Cosmetic Act.
DATES: The announcement of the
guidance is published in the Federal
Register on October 6, 2021.
ADDRESSES: You may submit either
electronic or written comments on
Agency guidances at any time as
follows:
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
E:\FR\FM\06OCN1.SGM
06OCN1
]]>Agencies
[Federal Register Volume 86, Number 191 (Wednesday, October 6, 2021)]
[Notices]
[Page 55616]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-21807]
[[Page 55616]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Lead Exposure and Prevention Advisory Committee
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the CDC
announces the following meeting for the Lead Exposure and Prevention
Advisory Committee (LEPAC). This meeting is open to the public by
teleconference but advance registration by November 19, 2021 is needed
to receive the information to join the meeting. The registration link
is https://www.zoomgov.com/webinar/register/WN_qeMSB7npRJ23PTV6t1KMtQ.
DATES: The meeting will be held on December 3, 2021, from 9:00 a.m. to
4:15 p.m., EST.
ADDRESSES: Register in advance at https://www.zoomgov.com/webinar/register/WN_qeMSB7npRJ23PTV6t1KMtQ to receive the information to join
the meeting.
FOR FURTHER INFORMATION CONTACT: Alexis Pullia, M.P.H., C.P.H.,
Committee Management Specialist, National Center for Environmental
Health, CDC, 4770 Buford Highway, Atlanta, GA, 30341, Telephone: (770)
488-3300; Email: [email protected].
SUPPLEMENTARY INFORMATION:
Purpose: The Lead Exposure and Prevention Advisory Committee was
established under Section 2203 of Public Law 114-322, the Water
Infrastructure Improvements for the Nation Act; 42 U.S.C. 300j-27,
Registry for Lead Exposure and Advisory Committee. The Secretary,
Department of Health and Human Services (HHS) and by delegation, the
Director, CDC and Administrator, NCEH/ATSDR, are authorized under
Section 2203 of Public Law 114-322 (42 U.S.C. 300j-27) to review
research and Federal programs and services related to lead poisoning
and to identify effective services and best practices for addressing
and preventing lead exposure in communities.
The LEPAC is charged with providing advice and guidance to the
Secretary, HHS, and the Director, CDC and Administrator, ATSDR, on (1)
reviewing Federal programs and services available to individual
communities exposed to lead; (2) reviewing current research on lead
exposure to identify additional research needs; (3) reviewing and
identifying best practices, or the need for best practices regarding
lead screening and the prevention of lead poisoning; (4) identifying
effective services, including services relating to healthcare,
education, and nutrition for individuals and communities affected by
lead exposure and lead poisoning, including in consultation with, as
appropriate, the lead exposure registry as established in Section 2203
(b) of Public Law 114-322; and (5) undertaking any other review or
activities that the Secretary determines to be appropriate.
Matters To Be Considered: The agenda will include updates on the
blood lead reference value, lead-related activities from Federal LEPAC
Members, the 1988 CLIA Amendment, and from Federal environmental
justice efforts focused on lead, a discussion of best practices for
increasing and enhancing screening in underserved populations, and
presentations on mapping efforts to identify populations at higher risk
of lead exposure and Lead Safe Cleveland. Agenda items are subject to
change as priorities dictate.
Public Participation
Procedure for Oral Public Comment: The public comment period is
scheduled on December 3, 2021 from 11:05 a.m. until 11:20 a.m.
Individuals wishing to make a comment during the public comment period,
please email your name, organization, and telephone number by November
19, 2021, to [email protected]
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-21807 Filed 10-5-21; 8:45 am]
BILLING CODE 4163-18-P
